Artemisinin Combination Therapy Market Size Trends, Analysis, and Forecast till 2035
Description
The Artemisinin Combination Therapy Market Report offers an in-depth exploration of emerging market trends, driving factors, challenges, and key segments that shape the industry. It includes a thorough examination of regulatory frameworks, company profiles, and the latest industry developments. The report delves into product development, positioning strategies, and the impact of new technologies on the market landscape. By identifying challenges and opportunities, the report provides a detailed roadmap for market growth.
In order to treat malaria, artemisinin combination therapy (ACT) combines an artemisinin-based chemical with one or more partner medications, boosting effectiveness and lowering the possibility of drug resistance. The market for artemisinin combination treatments has grown in response to the high incidence of malaria, especially in Southeast Asia and sub-Saharan Africa, and the drug's potent ability to combat drug-resistant strains of Plasmodium falciparum.
The WHO's funding programs and standards, together with other global health initiatives, have reduced the cost and increased the accessibility of ACTs. Furthermore, continuous improvements in pharmaceuticals have improved patient compliance and treatment efficacy, both of which have fueled market growth.
Report Highlights:
Artemisinin combination therapy market size is valuated at USD 684.4 Million in 2025.
Target Market size is estimated to be valuated at USD 1409.2 Million by 2035 and at a CAGR of 8.3%.
Artemether Lumefantrine has the biggest artemisinin combination therapy market share.
Government health facilities have the largest artemisinin combination therapy market share.
North America is dominating region in the artemisinin combination therapy market share over the forecast period.
The Asia Pacific region is seeing the fastest growth in the artemisinin combination therapy market growth.
Key Highlights:
In January 2019, Researchers gathered in Bangkok to launch the Developing Triple Artemisinin-based Combination Therapies (DeTACT) Project. Under the direction of MORU and supported by UKaid and the UK Department for International Development (DfID), DeTACT is a massive 14-site study spread across 8 African and 5 Asian nations. Its goal is to use combinations of already available antimalarial drugs to examine the safety, tolerability, and efficacy of two Triple Artemisinin Combination Therapy (TACT) combinations.
Report Analysis:
Global Importance of Artemisinin Combination Therapy:
Since the World Health Organization recommends Artemisinin Combination Therapy (ACT) as the first-line treatment for uncomplicated Plasmodium falciparum malaria, the most serious form of the disease, ACT is significant on a worldwide scale. When taken properly, ACT offers quick and extremely efficient parasite elimination with cure rates above 95%. It guarantees total parasite eradication and helps stop the emergence of treatment resistance by combining a longer-acting companion medication with a fast-acting artemisinin derivative. ACT is widely used in areas where malaria is endemic, including sub-Saharan Africa, Southeast Asia, and parts of South America. It is crucial for lowering the number of deaths from malaria and halting its global spread.
Segmentation:
By Therapy Type:
Novartis AG
KPC Pharmaceuticals, Inc
Shanghai Fosun Pharmaceutical Group Co., Ltd.
Ajanta Pharma Ltd.
Cipla
Ipca Laboratories Ltd.
NEM Laboratories
Bliss GVS
SHINPOONG.CO,.LTD
Dr. Reddy’s Laboratories Ltd
Manus Bio Inc.
AdvaCare Pharma
What You’ll Gain from This Report:
FAQs:
Key Questions Answered in the Report.
1. What was the Artemisinin Combination Therapy Market size in 2025?
2. What is projected growth rate of the Artemisinin Combination Therapy Market during 2025-2035?
3. What are the key factors driving the Artemisinin Combination Therapy Market growth?
4. What are leading players in the Artemisinin Combination Therapy Market ?
5. What are the key regions analyzed in the Artemisinin Combination Therapy Market ?
6. Which region is dominating in the Artemisinin Combination Therapy Market ?
In order to treat malaria, artemisinin combination therapy (ACT) combines an artemisinin-based chemical with one or more partner medications, boosting effectiveness and lowering the possibility of drug resistance. The market for artemisinin combination treatments has grown in response to the high incidence of malaria, especially in Southeast Asia and sub-Saharan Africa, and the drug's potent ability to combat drug-resistant strains of Plasmodium falciparum.
The WHO's funding programs and standards, together with other global health initiatives, have reduced the cost and increased the accessibility of ACTs. Furthermore, continuous improvements in pharmaceuticals have improved patient compliance and treatment efficacy, both of which have fueled market growth.
Report Highlights:
Artemisinin combination therapy market size is valuated at USD 684.4 Million in 2025.
Target Market size is estimated to be valuated at USD 1409.2 Million by 2035 and at a CAGR of 8.3%.
Artemether Lumefantrine has the biggest artemisinin combination therapy market share.
Government health facilities have the largest artemisinin combination therapy market share.
North America is dominating region in the artemisinin combination therapy market share over the forecast period.
The Asia Pacific region is seeing the fastest growth in the artemisinin combination therapy market growth.
Key Highlights:
In January 2019, Researchers gathered in Bangkok to launch the Developing Triple Artemisinin-based Combination Therapies (DeTACT) Project. Under the direction of MORU and supported by UKaid and the UK Department for International Development (DfID), DeTACT is a massive 14-site study spread across 8 African and 5 Asian nations. Its goal is to use combinations of already available antimalarial drugs to examine the safety, tolerability, and efficacy of two Triple Artemisinin Combination Therapy (TACT) combinations.
Report Analysis:
Global Importance of Artemisinin Combination Therapy:
Since the World Health Organization recommends Artemisinin Combination Therapy (ACT) as the first-line treatment for uncomplicated Plasmodium falciparum malaria, the most serious form of the disease, ACT is significant on a worldwide scale. When taken properly, ACT offers quick and extremely efficient parasite elimination with cure rates above 95%. It guarantees total parasite eradication and helps stop the emergence of treatment resistance by combining a longer-acting companion medication with a fast-acting artemisinin derivative. ACT is widely used in areas where malaria is endemic, including sub-Saharan Africa, Southeast Asia, and parts of South America. It is crucial for lowering the number of deaths from malaria and halting its global spread.
Segmentation:
By Therapy Type:
- Artemether Lumefantrine
- Artesunate Amodiaquine
- Dihydroartemisinin Piperaquine
- Artesunate Mefloquine
- Artesunate Sulfadoxine-Pyrimethamine
- Pyronaridine-Artesunate
- Others
- Hospitals
- Clinics
- Government Health Facilities
- NGO & International Health Organization Programs
- Others
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Russia
- Italy
- Spain
- Netherlands
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- Indonesia
- Malaysia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
Novartis AG
KPC Pharmaceuticals, Inc
Shanghai Fosun Pharmaceutical Group Co., Ltd.
Ajanta Pharma Ltd.
Cipla
Ipca Laboratories Ltd.
NEM Laboratories
Bliss GVS
SHINPOONG.CO,.LTD
Dr. Reddy’s Laboratories Ltd
Manus Bio Inc.
AdvaCare Pharma
What You’ll Gain from This Report:
- Regional & Country-Specific Insights: Unlock detailed market share analysis across key regions and countries, empowering you to pinpoint growth opportunities and optimize your strategic positioning.
- Guidance for Market Entry: Expert-backed strategies to overcome entry barriers, establish a foothold, and accelerate expansion in new or competitive markets.
- Reliable Long-Term Forecasts: Data-driven projections from 2025 to 2035, including pivotal milestones for 2025, 2026, and 2030, ensuring confident, future-proof investments.
- In-Depth Market Trend Analysis: Explore the forces shaping the industry—drivers, challenges, emerging opportunities, and risks—along with insights into high-growth sectors and potential obstacles.
- Proven Business Strategies: Actionable, data-backed recommendations tailored to key market segments, helping you maximize profitability and outperform competitors.
- Competitive Intelligence: Stay ahead with a clear view of industry trends, competitor strategies, and untapped market potential to refine your approach.
- Exclusive Company Profiles: In-depth analysis of top market players, including business models, financial performance, strategic initiatives, and recent developments.
- Innovative Supply Chain Trends: Discover the latest technological advancements transforming supply chains—boosting efficiency, cutting costs, and driving innovation.
FAQs:
Key Questions Answered in the Report.
1. What was the Artemisinin Combination Therapy Market size in 2025?
2. What is projected growth rate of the Artemisinin Combination Therapy Market during 2025-2035?
3. What are the key factors driving the Artemisinin Combination Therapy Market growth?
4. What are leading players in the Artemisinin Combination Therapy Market ?
5. What are the key regions analyzed in the Artemisinin Combination Therapy Market ?
6. Which region is dominating in the Artemisinin Combination Therapy Market ?
Table of Contents
179 Pages
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Preview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Therapy Type
- Market Snippet, By End User
- Market Snippet, By Region
- Opportunity Map Analysis
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- Product Launch
- Merger and Acquisitions
- Solid Oxide Electrolyzer Cell (SOEC) Analysis
- PEST Analysis
- Porter’s Analysis
- Pipeline Analysis
- The Benefits of ACT for Malaria
- Market Segmentation, By Therapy Type, Forecast Period up to 10 Years, (USD Mn)
- Overview
- Market Value and Forecast (USD Mn), and Share Analysis (%), Forecast Period up to 10 Years
- Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
- Segment Trends
- Artemether Lumefantrine
- Overview
- Market Size and Forecast (USD Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Artesunate Amodiaquine
- Overview
- Market Size and Forecast (USD Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Dihydroartemisinin Piperaquine
- Overview
- Market Size and Forecast (USD Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Artesunate Mefloquine
- Overview
- Market Size and Forecast (USD Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Artesunate Sulfadoxine-Pyrimethamine
- Overview
- Market Size and Forecast (USD Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Others
- Overview
- Market Size and Forecast (USD Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Market Segmentation, By End User, Forecast Period up to 10 Years, (USD Mn)
- Overview
- Market Value and Forecast (USD Mn), and Share Analysis (%), Forecast Period up to 10 Years
- Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
- Segment Trends
- Hospitals
- Overview
- Market Size and Forecast (USD Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Clinics
- Overview
- Market Size and Forecast (USD Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Government Health Facilities
- Overview
- Market Size and Forecast (USD Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- NGO & International Health Organization Programs
- Overview
- Market Size and Forecast (USD Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Others
- Overview
- Market Size and Forecast (USD Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Market Segmentation, By Region, Forecast Period up to 10 Years, (USD Mn)
- Overview
- Market Value and Forecast (USD Mn), and Share Analysis (%), Forecast Period up to 10 Years
- Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
- Regional Trends
- North America
- Market Size and Forecast (USD Mn), By Therapy Type, Forecast Period up to 10 Years
- Market Size and Forecast (USD Mn), By End User, Forecast Period up to 10 Years
- Market Size and Forecast (USD Mn), By Country, Forecast Period up to 10 Years
- U.S.
- Canada
- Asia Pacific
- Market Size and Forecast (USD Mn), By Therapy Type, Forecast Period up to 10 Years
- Market Size and Forecast (USD Mn), By End User, Forecast Period up to 10 Years
- Market Size and Forecast (USD Mn), By Country, Forecast Period up to 10 Years
- China
- India
- Japan
- Australia
- Indonesia
- Malaysia
- South Korea
- Rest of Asia Pacific
- Europe
- Market Size and Forecast (USD Mn), By Therapy Type, Forecast Period up to 10 Years
- Market Size and Forecast (USD Mn), By End User, Forecast Period up to 10 Years
- Market Size and Forecast (USD Mn), By Country, Forecast Period up to 10 Years
- Germany
- U.K.
- France
- Russia
- Italy
- Spain
- Netherlands
- Rest of Europe
- Latin America
- Market Size and Forecast (USD Mn), By Therapy Type, Forecast Period up to 10 Years
- Market Size and Forecast (USD Mn), By End User, Forecast Period up to 10 Years
- Market Size and Forecast (USD Mn), By Country, Forecast Period up to 10 Years
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East and Africa
- Market Size and Forecast (USD Mn), By Therapy Type, Forecast Period up to 10 Years
- Market Size and Forecast (USD Mn), By End User, Forecast Period up to 10 Years
- Market Size and Forecast (USD Mn), By Country, Forecast Period up to 10 Years
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
